Clinical Trials Browser

INDUSTRY × Melphalan × 1 year × Clear all

NCT06607458 2026-03-13

DEL-LIVER

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04150042 2026-01-29

SHARON

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 2 FDA

Multiple Myeloma